THE Therapeutic Goods Administration (TGA) has announced its approval of Latuda (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as "an important therapy" for young patients with this debilitating mental illness.
Latuda has a streamlined authority required PBS listing for schizophrenia.
Latuda PI is at guildlink.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 18
